miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma

Table 2 Correlation analysis of clinical outcomes with miR-106b expression profiles (n = 108)¹

	Patient numbersn(%)	Pvalue	Significant2
Underlying liver disease		0.374	NS
Liver cirrhosis	39 (36)
Non-cirrhosis	69 (64)
HCC differentiation
Well vs moderate	24 (22) vs 74 (69)	0.036	a
Well vs poor	24 (22) vs 9 (8)	0.015	a
Moderate vs poor	74 (69) vs 9 (8)	0.238	NS
Unknown	1
Microvascular invasion		0.856	NS
Yes	30 (28)
No	78 (72)
Tumor number		0.798	NS
Single tumor	87 (81)
> 1 tumor	21 (19)
Tumor size (cm)3		0.812	NS
< 5	72 (67)
≥ 5	36 (33)
Recurrence after surgery		0.687	NS
Yes	58 (54)
No	50 (46)
Pathological staging
Stage I vs stage II	39 (36) vs 51 (47)	0.968	NS
Stage I vs stage III	39 (36) vs 18 (17)	0.625	NS
Stage II and stage III	51 (47) vs 18 (17)	0.575	NS
		Total patients, n = 108

¹The patient characteristics are summarized based on the clinical outcomes. Demographic and clinical features of patients were retrospectively analyzed and correlated with the miR-106b expression profiles;

²The correlation between miR-106b expression values and the patient numbers of each clinical outcome parameter were analyzed using Mann-Whitney U tests.

^aP < 0.05 was considered significant;

³Tumor size represents the maximum diameter of the tumor nodule. The diameter of the largest nodule was 16 cm. NS: No significant difference; HCC: Hepatocellular carcinoma.